Replimune Group Inc

NASDAQ:REPL   11:46:03 AM EDT
42.42
+1.44 (+3.51%)
Products, Regulatory

Replimune Provides Initial safety, efficacy data from single agent RP2 portion of Phase 1 clinical trial of RP2 in combination with Opdivo in patients with solid tumors

Published: 10/14/2020 16:55 GMT
Replimune Group Inc (REPL) - Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (sitc) Annual Meeting.
Replimune Group-data With Co's Lead Product Candidate, Rp1, Alongwith Initial Single Agent Safety and Efficacy Data With Rp2 in Advanced Solid Tumors.
Replimune Group - Phase 1 Clinical Data Supports Safety & Efficacy of Single Agent P2 in Patients With Difficult to Treat Advanced Cancers.
Replimune Group Inc - Phase 1 Clinical Data Supports Safety and Efficacy of Single Agent P2, Includes Demonstration of Uninjected Tumor Response.
Replimune Group Inc -rp1 & Nivolumab Have Continued to Be Well Tolerated, With Continued Promising Anti-tumor Activity in Patients With Skin Cancers.
Replimune-rp1,nivolumab Continued to Be Well Tolerated in Patients With Anti-pd1 Refractory&other Difficult to Treat Melanomas, &in Patients With Cscc.
Replimune - in Phase 1/2 Clinical Trial of Rp1 Combined With Nivolumab,enrollment of Further 125 Patient Anti-pd1 Refractory Cutaneous Melanoma Cohort.